Trial Profile
Phase Ib/II Multicentric Study Combining Glasdegib (PF-04449913) With Temozolomide in Patients With Newly Diagnosed Glioblastoma, Safety and Preliminary Efficacy for the Combination
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Dec 2023
Price :
$35
*
At a glance
- Drugs Glasdegib (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms GEINO 1602; GEINOGLAS
- 24 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 22 Nov 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 22 Nov 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2024.